Lasa Supergenerics Ltd

Stage 4 · Declining · week 14

As of 19 Oct 2026, Lasa Supergenerics is in Stage 4 — declining, a downtrend, in week 14 (since 13 Jul 2026). It closed at ₹4.91, 64.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 39.8% of stocks are in Stage 2.

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. More about the company

₹4.9
-4.84% today
₹25 Cr · Micro cap
Market Neutral — FadingHealth Care 39.8% in Stage 2-8.8 pts / 20dPharmaceuticals 50.0%-3.8 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LASA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-64.7%
₹4.9 lo₹13.9 hi
64.7% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 14
1w13w26w
Week 14 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-38.6%
200 DMA: ₹8 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.02x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -10.1% vs MA50 -5.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-30.7%
3M
-34.6%
6M
-31.7%
YTD
-47.7%
1Y
-58.2%
Sector
Health Care
↓ Peaking
Stage 2%
39.8%
20d Δ
-8.8pp
1M return
-6.3%
3M return
-3.3%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.0%
20d Δ
-3.8pp
1M return
-4.7%
3M return
-3.1%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-06-22 → 2026-10-19
S4 15w
S4 30w
S4 26w
S4 14w
2023-06-222026-10-19
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 6w → S1 5w → S2 7w → S3 5w → S2 12w → S3 6w → S4 15w → S1 7w → S2 7w → S3 8w → S2 6w → S3 1w → S4 30w → S1 10w → S4 26w → S1 6w → S4 14w current
Total tracked: 173 weeks across 18 stage runs.
Scan Membership
Breakout Watch
Latest: 2025-01-06
2 appearances in last 60 days. First seen: 2024-09-25.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-19S4
Wk 14 · Vol 1.02x
2026-10-12S4
Wk 13 · Vol 4.90x
2026-10-05S4
Wk 12 · Vol 1.80x
2026-09-28S4
Wk 11 · Vol 0.66x
2026-09-21S4
Wk 10 · Vol 0.51x
2026-09-15S4
Wk 10 · Vol 0.54x
2026-09-09S4
Wk 9 · Vol 1.41x
2026-09-08S4
Wk 9 · Vol 1.09x
2026-09-07S4
Wk 9 · Vol 0.54x
2026-09-04S4
Wk 8 · Vol 0.75x
2026-09-03S4
Wk 8 · Vol 0.79x
2026-09-02S4
Wk 8 · Vol 0.64x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 4 · -16.0% from hi
8.4
KOPRAN
wk 20 · -4.3% from hi
7.4
LAURUSLABS
wk 26 · -0.0% from hi
7.3
ZIMLAB
wk 23 · -9.5% from hi
6.9
Moving averages & range
50 DMA
₹6.9
200 DMA
₹8
52W High
₹13.9
52W Low
₹4.9
5D Low
₹4.9
Resistance levels (recent highs)
20d High
₹7.3
60d High
₹8
120d High
₹8.7
250d High
₹13.9
Next resistance
+47.9%
to 20d High
Ask the Market AI about LASAAsk →
P/E (TTM)
2.3
Forward —
About this companyHealth Care· Pharmaceuticals

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-19. Past data patterns are not indicative of future results. This page is a data analytics tool only.